A liver donor does not have to share your exact blood type, but a compatible match is strongly preferred and produces the best outcomes. The ABO blood group system follows similar compatibility rules as blood transfusion: type O is a universal donor, type AB is a universal recipient, and identical types are ideal. When no compatible donor is available, transplant teams can now cross the blood-type barrier using desensitization treatments, though this path carries higher risks of graft complications. The science behind ABO-incompatible liver transplantation has evolved dramatically, turning what was once considered nearly impossible into a viable option in specific circumstances.
How Blood Type Matching Works in Liver Transplants
Blood type compatibility for liver donation follows a hierarchy. The best scenario is an ABO-identical transplant, where donor and recipient share the same blood type (A to A, B to B, and so on). The next tier is ABO-compatible, meaning the blood types are not identical but are still harmonious. A type O donor can give to anyone, and a type AB recipient can receive from anyone. This mirrors the logic of blood transfusion compatibility. The third tier, ABO-incompatible, means the donor has blood-type antigens the recipient’s immune system will recognize as foreign and attack. An example would be a type A donor giving to a type B recipient.
Most transplant programs aim for identical or compatible matches whenever possible. In deceased-donor allocation systems, blood type matching is built into the organ-assignment algorithm. But in living-donor transplantation, where a family member or friend volunteers to donate part of their liver, the willing donor sometimes has an incompatible blood type. That mismatch used to be a dealbreaker. It no longer is, though it does change the treatment plan considerably.
Why Mismatched Blood Types Cause Problems
When a liver with incompatible blood-type antigens is transplanted, the recipient’s immune system produces antibodies that target those foreign antigens on the lining of blood vessels within the new organ. This triggers a process called antibody-mediated rejection. Early studies of ABO-incompatible liver grafts that failed showed widespread hemorrhagic damage with blood clotting throughout the organ, along with antibody and immune-protein deposits concentrated in the arteries of the graft.
1PubMed Central. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriersA specific immune marker called C4d, which flags areas where antibodies have activated the immune cascade, appears in about half of ABO-incompatible liver recipients. Patients with strong C4d staining and high post-transplant antibody levels had dramatically worse survival compared to those without it.
2PubMed. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantationThe liver does have a natural advantage over other organs in this regard. Compared to hearts and lungs, liver and kidney grafts tend to provoke less aggressive immune responses. Researchers believe organ-specific factors play a role in driving how intensely the immune system reacts after transplantation.
3PubMed Central. Why some organ allografts are tolerated better than others: new insights for an old questionThis relative immune tolerance is part of why crossing the blood-type barrier is more feasible with livers than with some other organs, though it does not eliminate the risks.
How Transplant Teams Cross the Blood-Type Barrier
The breakthrough that made ABO-incompatible liver transplants practical was the development of desensitization protocols. These are treatment regimens given before surgery to suppress the recipient’s ability to produce the antibodies that would attack the mismatched graft. The typical protocol involves two main components: a drug called rituximab, which depletes the immune cells responsible for making antibodies, and plasma exchange, which physically filters existing antibodies out of the bloodstream.
Rituximab is usually given as a single intravenous infusion two to three weeks before surgery. The dose varies between centers. Some programs use a standard body-surface-area-based dose, while others have found that lower fixed doses work as well.
4American Journal of Transplantation. ABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab One center reported successful outcomes using just 200 mg of rituximab combined with four sessions of plasma filtration before transplant.5PubMed Central. ABO-Incompatible Living Donor Liver Transplantation with Reduced Rituximab Dose: A Retrospective Analysis of 65 Patients – Can We Fast-Track Liver Transplant Surgery and Improve Long-Term Survival?
The goal of plasma exchange is to drive down the recipient’s antibody levels to a target threshold before the operation. Once antibody titers are low enough, the transplant proceeds, and standard anti-rejection drugs are used afterward. The protocol has improved steadily since rituximab entered transplant practice around 2003, and outcomes have improved with it.
6PubMed. Current progress in ABO-incompatible liver transplantationSurvival Outcomes With Incompatible Transplants
The survival picture is more nuanced than a simple “compatible is better.” A large meta-analysis comparing ABO-incompatible to ABO-compatible liver transplants found that graft survival (whether the transplanted liver itself keeps working) was consistently lower in the incompatible group at one, three, five, and ten years. But patient survival, which accounts for the possibility of retransplantation, showed no significant difference at one, three, or five years. It was only at the ten-year mark that patient survival diverged meaningfully between the two groups.
7PubMed Central. Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysisResults from centers using modern rituximab-based protocols are even more encouraging. A study of 235 ABO-incompatible living-donor transplant recipients reported one-year and three-year patient survival rates above 96% and 92%, respectively, with no significant difference compared to the compatible group. In-hospital mortality was actually lower in the incompatible group in that series, though the reasons likely relate to patient selection rather than any advantage of mismatching.
4American Journal of Transplantation. ABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab Another study looking specifically at adult living-donor transplants found five-year survival rates of about 71% for both incompatible and compatible recipients, with the caveat that biliary complications were more common in the incompatible group.
8PubMed Central. Adult Living Donor Liver Transplantation Across ABO-IncompatibilityThe Biliary Complication Problem
If there is one persistent thorn in ABO-incompatible liver transplantation, it is damage to the bile ducts. The bile duct system inside the transplanted liver is particularly vulnerable to antibody-mediated injury. This can cause a pattern of scarring and narrowing called ischemic-type biliary lesions, which can severely impair the graft’s function months or years after the transplant.
9PubMed. Ischemic-type biliary complications after orthotopic liver transplantationABO incompatibility is recognized as a risk factor for these lesions alongside other causes like blood supply problems and pre-existing autoimmune liver diseases.
10PubMed. Causes and consequences of ischemic-type biliary lesions after liver transplantation This is the main reason the gap between graft survival and patient survival exists in the data: the transplanted liver may fail due to biliary damage, requiring interventional procedures or even retransplantation, even though the patient survives. Modern desensitization has reduced but not eliminated this complication, and it remains the primary area where ABO-incompatible transplants lag behind compatible ones.
Children Have an Advantage
Pediatric patients tolerate ABO-incompatible liver transplants better than adults, and the reasons are immunological. A child’s immune system, especially in infancy and early childhood, is not fully mature. Immature immune cells are far more likely to develop tolerance to foreign antigens than adult immune cells. Research suggests that in adults with fully developed immune systems, the dose of foreign antigen needed to induce tolerance is roughly 30 times higher than in immature cells.
11Annals of Transplantation. Incomplete Immune Tolerance in Pediatric ABO-Incompatible Liver Transplantation: Insights From Donor-Specific Antibody TitersThis biological reality means young children can receive ABO-incompatible grafts with less intensive desensitization and still achieve good outcomes. Some pediatric centers perform these transplants routinely when a parent is the only available donor and the blood types don’t match. The window of advantage narrows as children age and their immune system matures, but for infants and toddlers in particular, the blood-type barrier is much lower than it is for adults.
Emergency Situations and Incompatible Grafts
When someone is dying of acute liver failure and no compatible organ is available, transplant teams will use whatever liver they can get. An early landmark analysis found that patients receiving ABO-incompatible grafts in emergencies had a one-year survival rate of about 66%, and that roughly half would eventually need retransplantation. The authors argued this was still justified because the alternative was death.
12The Lancet. Liver transplantation across ABO blood group barriersEmergency use of mismatched grafts has been reported in cases of fulminant hepatitis, where the liver fails so rapidly that waiting for a compatible organ is not an option.
13PubMed. Emergency liver transplantation for fulminant hepatitis In Scandinavia, a review of ABO-incompatible transplants performed over 15 years found that more than half were done on urgent indications, underscoring that this is frequently a last-resort lifesaving measure rather than a planned first choice.
6PubMed. Current progress in ABO-incompatible liver transplantationPaired Donor Exchange Programs
There is a clever workaround for the blood-type problem in living-donor transplantation that avoids desensitization entirely: paired exchange. If Patient A has a willing donor whose blood type is incompatible with A but compatible with Patient B, and Patient B has a willing donor compatible with A, the donors swap. Each patient gets a compatible liver without any need to cross the ABO barrier.
One of the largest reported programs performed 16 paired exchanges over six years. The initial incompatibilities spanned a range of ABO mismatch combinations. After swapping donors, all 16 pairs ended up with either ABO-identical or ABO-compatible matches.
14PubMed. Exchange living donor liver transplantation to overcome ABO incompatibility in adult patients Emergency paired exchanges have also been reported, with four simultaneous operations (two donor surgeries and two recipient transplants) coordinated on the same day to avoid two incompatible transplants.
15PubMed. Paired donor interchange to avoid ABO-incompatible living donor liver transplantationPaired exchange is more established in kidney transplantation, where national registries match hundreds of pairs each year. Liver exchange programs are smaller and less common, partly because liver donation surgery is more complex for the donor and timing is harder to coordinate. But where they exist, they offer an elegant solution that sidesteps the immunological risks of incompatibility altogether.
Does Rh Factor Matter?
Most discussions of blood-type matching in transplantation focus on the ABO system, but the Rh factor (the positive or negative part of your blood type) also plays a role, albeit a subtler one. A study of liver transplant outcomes found that Rh-mismatched grafts had a higher rate of biliary complications compared to Rh-matched grafts, about 30% versus 17%. Statistical analysis confirmed that Rh mismatch was an independent risk factor for biliary problems, roughly doubling the risk.
16PubMed Central. Liver transplantation across Rh blood group barriers increases the risk of biliary complicationsDespite this finding, Rh matching is not typically considered a hard requirement in liver transplant allocation. The increased risk is real but modest compared to ABO incompatibility, and in practice, Rh mismatch is accepted when an otherwise good organ is available. Still, it is worth noting that “blood type matching” in transplantation is not just about the A, B, O, and AB labels most people think of.
Blood Transfusion During Mismatched Transplants
Liver transplant surgery is a major operation that often requires blood products, and ABO-incompatible transplants add a layer of complexity to transfusion management. The recipient and the donor have different blood types, so transfusion products have to be chosen carefully to avoid triggering the very antibody reactions the desensitization protocol was designed to prevent. In reported cases, recipients received red blood cells of their own blood type, while plasma was selected to be antibody-neutral. AB plasma, which contains no anti-A or anti-B antibodies, is commonly used. None of the patients in one case series developed transfusion-related complications with this approach.
17PubMed Central. Anaesthetic implications and transfusion practices in ABO incompatible living donor liver transplantation: Case seriesThis careful blood product selection is another reason ABO-incompatible transplants require experienced teams. The anesthesiologists, blood bank staff, and surgeons all need to coordinate on which products are safe, and there is no room for a routine “grab whatever is available” approach.
Tailoring Immunosuppression and Preventing Infections
The desensitization regimen is powerful, but that power comes with a cost: it broadly suppresses the recipient’s immune defenses. Rituximab wipes out the B cells that produce not only the harmful anti-donor antibodies but also the protective antibodies that fight infections. Combined with the standard anti-rejection drugs given after transplant, this creates a window of heightened vulnerability to bacterial, viral, and fungal infections.
Researchers are working on ways to identify which patients are truly at high risk for antibody-mediated rejection and which could safely receive less aggressive treatment. One promising avenue involves genetic variations in receptors on immune cells that affect how well rituximab depletes B cells. Patients whose genetics make them strong responders to rituximab might need lower doses, reducing the infection risk without sacrificing rejection protection.
18PubMed Central. Current Status of ABO-incompatible Liver Transplantation This kind of personalized approach is still being developed, but it reflects a broader shift in transplant medicine toward calibrating treatment intensity to the individual rather than applying the same protocol to everyone.
Enzymatic Conversion of Donor Organs
A radically different approach to the blood-type barrier is to change the donor organ’s blood type rather than suppress the recipient’s immune response. Researchers have demonstrated that enzymes can strip blood-group antigens off the lining of donor kidney blood vessels while the organ is maintained on a perfusion machine outside the body. In one study, type A kidneys lost roughly 80% of their A antigens after just two hours of enzyme treatment, effectively converting them toward a universal type O state.
19Nature Communications. Enzymatic conversion of human blood group A kidneys to universal blood group OThis work has so far been demonstrated in kidneys, not livers, but the underlying concept applies to any organ with blood-group antigens on its vascular lining. If the technique proves durable and can be scaled to livers, it could eventually make blood-type matching irrelevant for transplantation. The organs would arrive as universal donors regardless of the original blood type. That future is still years away from clinical reality, but the proof of concept is striking and could reshape how transplant waitlists function.